knowledge -WSS

knowledge

author：fashion 2025-10-03 00:07:25 - browse：1833

Photo illustration of Chris Viehbacher -- biotech coverage from STAT — Chris Viehbacher took over as Biogen CEO in November. Suzanne Kreiter/Globe staff; Photo illustration Alex Hogan/STAT

This was supposed to be the new Biogen. When Chris Viehbacher, a respected pharmaceutical executive, took over as CEO in November, Wall Street saw him as a steadying force for the wayward company and a strong personality who would stand up to its quarrelsome board.

Instead, Biogen’s board has saddled Viehbacher with the first crisis of his tenure at the company. Alex Denner, a long-time director, nominated a biotech executive who is also the mother of his child to succeed him on the board, and Biogen chose not to disclose the couple’s relationship to shareholders, an omission that shocked people close to the company and undermined the notion that Biogen was changing for the better.

“It’s just disappointing to see after all the criticism that has been levied at the company over the last few years, there really seems to be no self-awareness going into this recommendation,” said Brian Skorney, a securities analyst at Baird who covers Biogen.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Drinking less cuts risk of oral cavity, esophageal cancer: Report

WSS

Biden's 'march

Pregnant women don't need prenatal multivitamins, study concludes

Streamlined flu vaccines recommended by FDA advisory panel

Longer MASH drug regimen improved liver, Akero study finds

Medicare drug price negotiation hearing pits pharma v Biden admin

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

knowledge

knowledge

explore

Cancer drug shortages should be causing more outrage

For AI in health care standards, federal regulators join with industry group

The cancer drug shortage isn’t new — and neither are the solutions

Change Healthcare: What is it, why does its cyberattack matter?

How to save PrEP access — and even expand it

Readout Newsletter: The latest on Moderna, Apellis, and Merck

Continuity nursing helped my family in our darkest PICU moments

Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

Novavax promises a turnaround & Lilly roils the obesity market

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

knowledge

Medicare drug price negotiation continues, as pharma counteroffers

Grail spinoff by Illumina should end disastrous merger attempt

Pregnant women don't need prenatal multivitamins, study concludes

Fetal cell organoids grown from amniotic fluid, study finds

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

hotspot

explore

focus

entertainment